Concepts represent early planning stages for program announcements, requests for applications, or solicitations for Council's input. If NIAID publishes an initiative from one of these concepts, we link to it below. To find initiatives, go to Opportunities & Announcements.
NB: Council approval does not guarantee that a concept will become an initiative.
Table of Contents
- Autoimmunity Centers of Excellence, Basic Component/Clinical Component
- NIAID Division of Allergy, Immunology, and Transplantation: Immune-Mediated Diseases Clinical Products Center (CPC)
- Investigations on Primary Immunodeficiency Diseases
- SBIR Radiation and Nuclear Countermeasures Program
- Immunity in the Elderly
- Immune Epitope Database and Analysis Program
Request for Applications—proposed FY 2019 initiative
Contact: David Johnson
Objective: To renew the Autoimmunity Centers of Excellence (ACE) program, a cooperative network of integrated basic, preclinical, and clinical research centers, which is designed to:
- Conduct cooperative single- and multi-site clinical trials and studies of mechanisms of action of new or re-purposed candidate tolerance inducing and immune modulating interventions in autoimmune diseases.
- Accelerate early translation of basic research findings into clinical application.
- Facilitate using clinical materials for basic research studies.
- Enhance the exchange of information between basic scientists and clinicians and among various specialists involved in treating autoimmune diseases.
- Promote a collaborative approach to clinical and basic research among multiple institutions in various geographic areas.
Description: ACE includes multidisciplinary, interactive research projects focused on elucidating the basic mechanisms of autoimmunity, understanding of self-tolerance and immune modulation in autoimmune diseases, and an integrated clinical component for piloting of novel immunotherapies for autoimmune diseases. The inclusion of central cores and an integrated clinical network facilitates clinical trials and studies, basic science, and the application of basic research findings in the clinical setting. The program does not restrict the focus to particular autoimmune diseases. Programs studying more than one disease are encouraged.
- Structural changes made in the program for the current cycle, most notably the separation into clinical (UM1) from basic (U19) research centers, as well as requiring that applications describe more developed proposals, largely succeeded in accelerating clinical trial development. Further acceleration will be sought by requiring additional documentation of feasibility and readiness, along the lines already required in applications for support of investigator-initiated clinical trials.
- To strengthen the involvement of the clinical centers in the basic science, clinical centers will be required to propose a collaborative project.
- To allow better planning and quicker initiation of the collaborative projects, they will receive a base funding through direct award to the Centers. They will also compete now for new and supplemental support from the Opportunity Fund.
- Finally, applicants will be invited to propose a sample management core. A single core, scoring well in peer review, may be awarded for the entire program.
NIAID Division of Allergy, Immunology, and Transplantation: Immune-Mediated Diseases Clinical Products Center (CPC)
For the published request for proposals, see the September 1, 2017 solicitation Immune-Mediated Diseases Clinical Products Center.
Program Announcement With Special Receipt, Referral, and/or Review Considerations—proposed FY 2019 initiative
Contact: Frosso Voulgaropoulou
Objective: This initiative will support research project grant (R01) applications that propose innovative investigations in primary immunodeficiency diseases. Of particular interest are identifying primary immunodeficiency diseases; characterizing their clinical, immunological, genetic, and molecular basis; and developing innovative therapies. Ex vivo studies with human specimens, studies with current or new animal models, and in vitro state-of-the-art technologies are encouraged.
Description: This initiative will support R01 applications with primary immunodeficiency disease-specific objectives and scope, using payline funding. The applications will be reviewed by a Center for Scientific Review Special Emphasis Panel convened using experts in primary immunodeficiency diseases. No changes from the currently active funding opportunity announcement are proposed.
Program Announcement—proposed FY 2019 initiative
Contact: Carmen Rios
Objective: To provide funds for preclinical product development of drugs and devices that could lead to eventual FDA licensure and inclusion of products in the Strategic National Stockpile, for potential use during a nuclear or radiological incident. Products of interest include medical countermeasures effective for the mitigation or treatment of acute radiation syndromes, radionuclide decorporation agents to treat internal contamination, and biodosimetry biomarkers/devices for determining triage and treatment strategies.
Description: This program will fund small business R43/R44 grants (Phase I, Phase II, and Phase IIB) to support developing safe and effective medical countermeasures to mitigate tissue injuries from exposure to ionizing radiation from a radiological or nuclear incident, developing drugs to remove internalized radionuclide contamination that can lead to a reduction in radiation-associated morbidities and mortalities, or biodosimetry biomarkers/devices for use in determining triage and treatment strategies for large numbers of potentially-exposed individuals. Specifically, this Program is intended to support research and development of the most promising new approaches (including but not limited to: biologics, drugs, cytokines, free radical scavengers, anti-inflammatory agents, antibiotics, cellular therapies, anti-fibrotics, and anti-apoptotics) as well as medical devices that assess, mitigate, and/or treat radiation-induced injuries.
For the published request for applications, see the October 25, 2017 Guide announcement, Immunity in the Elderly (R01, Clinical Trial Optional).
For the published request for proposals, see the November 17, 2017 solicitation, Immune Epitope and Analysis Resource Program.